These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34150443)

  • 21. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
    Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
    Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 Vaccination in Korea: Past, Present, and the Way Forward.
    Nham E; Song JY; Noh JY; Cheong HJ; Kim WJ
    J Korean Med Sci; 2022 Dec; 37(47):e351. PubMed ID: 36472087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations.
    Manoharan L; Olliaro P; Horby PW; Watson CH
    Trials; 2021 May; 22(1):370. PubMed ID: 34051840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
    JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
    Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.
    Kumar V; Kumar S; Sharma PC
    Int Immunopharmacol; 2022 Oct; 111():109175. PubMed ID: 35994853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling and tracking Covid-19 cases using Big Data analytics on HPCC system platformm.
    Villanustre F; Chala A; Dev R; Xu L; LexisNexis JS; Furht B; Khoshgoftaar T
    J Big Data; 2021; 8(1):33. PubMed ID: 33614394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Living with covid-19.
    Ploumpidis D
    Psychiatriki; 2020; 31(3):197-200. PubMed ID: 33099460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs.
    Chopra D; Boparai JK; Bhandari B; Srivastava A; Gupta R
    Infect Disord Drug Targets; 2021; 21(7):e160921189260. PubMed ID: 33342420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Artificial intelligence as a fundamental tool in management of infectious diseases and its current implementation in COVID-19 pandemic.
    Kaur I; Behl T; Aleya L; Rahman H; Kumar A; Arora S; Bulbul IJ
    Environ Sci Pollut Res Int; 2021 Aug; 28(30):40515-40532. PubMed ID: 34036497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Reminder of Skin Cancer During the COVID-19 Pandemic.
    Šitum M; Filipović N; Buljan M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):58. PubMed ID: 34477068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artificial Intelligence (AI) applications for COVID-19 pandemic.
    Vaishya R; Javaid M; Khan IH; Haleem A
    Diabetes Metab Syndr; 2020; 14(4):337-339. PubMed ID: 32305024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
    Apaydın ÇB; Çınar G; Cihan-Üstündağ G
    Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.